$RZLT News
Last published 2d ago
- 2d agoRZLTGUGGENHEIM 3RD ANNUAL HEALTHCARE INNOVATION CONFERENCE - REZOLUTE INCEarnings Call TranscriptsAll right, good morning, and thank you for joining Guggenheim's third annual Healthcare Innovations Conference. I am Deb Chitt, and joining us today are Nevin Elam, founder and CEO of Resolute, and Sunil Karnavat, its ch
- 6d agoRZLTRezolute, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 9.01
- 6d agoRZLTRezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business UpdateGlobeNewswireREDWOOD CITY, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or the Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by
- 1w agoRZLTRezolute to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare, metabolic disease company focused on treating refractory hypoglycemia caused by any
- 4w agoRZLTRezolute Announces Completion of Enrollment in Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismGlobeNewswireTopline results expected mid-December 2026 REDWOOD CITY, Calif., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) (Rezolute or Company), a late-stage ultra-rare disease company focused on treating
- 2mo agoRZLTRezolute Provides Update on FDA Review of its Phase 3 sunRIZE Study Results in Congenital HyperinsulinismGlobeNewswireData from the Phase 3 sunRIZE study remains under review by FDA The OLE Phase of the study is ongoing, with a high participation rate and several indicators of improved glycemic control, including a notable reduction
- 2mo agoRZLTRezolute to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia
- 3mo agoRZLTRezolute to Participate in the BTIG Virtual Biotechnology ConferenceGlobeNewswireREDWOOD CITY, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia
- 4mo agoRZLTRezolute Highlights Results Presented from Natural History Outcomes Studies and its Ersodetug Clinical Program in Hyperinsulinism at Annual Meeting of the Endocrine SocietyGlobeNewswirePresentations included analyses of natural history and adverse outcomes in congenital hyperinsulinism (HI), as well as previously reported results from the Company's Phase 3 sunRIZE study in congenital HI and a case
- 5mo agoRZLTJeffries Global Healthcare Conference in New York - REZOLUTE INCEarnings Call TranscriptsHi, everyone. My name is Morrie Raycroft, and I'm one of the biotech analysts at Jefferies. I'd like to welcome Nevin Charles-Alam, the founder and CEO of Resolute. It's a late-stage ultra-rare disease company focused on
- 5mo agoRZLTRezolute Announces Four Presentations at the Upcoming Annual Meeting of the Endocrine SocietyGlobeNewswireREDWOOD CITY, Calif., June 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage ultra-rare disease company focused on treating refractory hypoglycemia caused by a
- 5mo agoRZLTRezolute Announces Positive Interim Data for its Phase 3 upLIFT Study of Ersodetug in Tumor HyperinsulinismGlobeNewswireStudy now 50% enrolled 6 of 8 participants have already met the responder criterion for the study's primary endpoint Topline results for the fully enrolled open-label study are expected in the second half of 2026
- 6mo agoRZLTRezolute Reports Third Quarter Fiscal 2026 Financial Results and Provides Business UpdateGlobeNewswireREDWOOD CITY, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of
- 6mo agoRZLTRezolute to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., May 11, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of
- 6mo agoRZLTRezolute Announces Oral Presentation of Results From its Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital Hyperinsulinism at the Pediatric Endocrine Society Annual MeetingGlobeNewswireIncludes results from additional continuous glucose monitoring (CGM)-based outcomes which demonstrate significant and consistent improvements in glycemic control in ersodetug treatment arms compared to placebo, across
- 6mo agoRZLTRezolute to Present Results from its Phase 3 sunRIZE Study in Congenital Hyperinsulinism at the Pediatric Endocrine Society (PES) Annual MeetingGlobeNewswireOral presentation will include previously announced topline results as well as pre-specified and post-hoc data updates REDWOOD CITY, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute"
- 7mo agoRZLTRezolute Provides Update on its Congenital Hyperinsulinism Program Following FDA MeetingGlobeNewswireREDWOOD CITY, Calif., March 24, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of
- 8mo agoRZLTRezolute to Participate in the Citizens Life Sciences ConferenceGlobeNewswireREDWOOD CITY, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of
- 8mo agoRZLTRZLT SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 8mo agoRZLTRZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezolutePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company")...
- 8mo agoRZLTINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 8mo agoRZLTRZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 8mo agoRZLTRZLT SECURITIES ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 9mo agoRZLTINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezolutePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company")...
- 9mo agoRZLTRezolute Reports Second Quarter Fiscal 2026 Financial Results and Provides Business UpdateGlobeNewswireREDWOOD CITY, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of
- 9mo agoRZLTINVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezolutePR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company")...
- 9mo agoRZLTRezolute to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026GlobeNewswireREDWOOD CITY, Calif., Feb. 04, 2026 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by all forms of
- 9mo agoRZLTRZLT INVESTOR NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 10mo agoRZLTUPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 10mo agoRZLTINVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLTGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 10mo agoRZLTINVESTIGATION: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLTPR NewswireFaruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Rezolute, Inc. ("Rezolute" or the "Company")...
- 10mo agoRZLTUPCOMING DEADLINE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RezoluteGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 10mo agoRZLTREZOLUTE INVESTIGATION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of RZLTGlobeNewswireFaruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Significant Losses In Rezolute To Contact Him Directly To Discuss Their Options If you suffered significant
- 10mo agoRZLTRZLT: Rezolute, Inc. Investigated for Securities Fraud; Block & Leviton Encourages Investors Who Have Lost Money to Contact the FirmGlobeNewswireBOSTON, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Block & Leviton is investigating Rezolute, Inc. (NASDAQ:RZLT) for potential securities law violations. Investors who have lost money in their Rezolute, Inc. investment
- 11mo agoRZLTRezolute Conference Call - REZOLUTE INCEarnings Call TranscriptsGood morning and welcome to the Sunrise Topline Data Conference Call. All participants will be in listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by z
- 11mo agoRZLTRezolute Announces Phase 3 sunRIZE Study Results in Congenital HyperinsulinismGlobeNewswireStudy did not meet the primary or key secondary endpoint 45% reduction in hypoglycemia events observed at top ersodetug dose (10 mg/kg) compared to 40% improvement in placebo arm Management to host conference call
- 1y agoRZLTRezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today
- 1y agoRZLTRezolute Investor Event - REZOLUTE INCEarnings Call TranscriptsGood day, and welcome to the Resolute Investor Event Conference Call. All participants will be in a listen-only mode. Should you need assistance, please signal a conference specialist by pressing the star key followed by
- 1y agoRZLTRezolute to Host Virtual Investor Event on Ersodetug Development ProgramGlobeNewswireREDWOOD CITY, Calif., Nov. 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today
- 1y agoRZLTRezolute to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today
- 1y agoRZLTRezolute Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)GlobeNewswireREDWOOD CITY, Calif., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ: RZLT), ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today
- 1y agoRZLTRezolute Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results and Provides Business UpdateGlobeNewswireREDWOOD CITY, Calif., Sept. 17, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today
- 1y agoRZLTRezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptEarnings Call Transcripts
- 1y agoRZLTRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor HyperinsulinismGlobeNewswireOpen-label study in as few as 16 tumor hyperinsulinism (HI) patients Study initiated and enrolling patients in the U.S. and Europe Topline data expected in the second half of 2026 REDWOOD CITY, Calif.,
- 1y agoRZLTRezolute to Participate in Upcoming Investor ConferencesGlobeNewswireREDWOOD CITY, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today
- 1y agoRZLTRezolute Appoints Seasoned Commercial Executive Sunil Karnawat as Chief Commercial OfficerGlobeNewswireREDWOOD CITY, Calif., Aug. 20, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism (HI),
- 1y agoRZLTRezolute to Participate in the BTIG Virtual Biotechnology ConferenceGlobeNewswireREDWOOD CITY, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (NASDAQ:RZLT) ("Rezolute" or the "Company"), a late-stage rare disease company focused on treating hypoglycemia caused by hyperinsulinism, today
- 1y agoRZLTRezolute Announces Completion of Enrollment in the Phase 3 sunRIZE Study of Ersodetug in Patients with Congenital HyperinsulinismGlobeNewswireTarget enrollment exceeded with 62 participants enrolled, including approximately 15 percent from U.S. sites Topline data is anticipated in December of 2025 REDWOOD CITY, Calif., May 28, 2025 (GLOBE NEWSWIRE) --
- 1y agoRZLTRezolute Reports Third Quarter Fiscal 2025 Financial Results and Provides Business UpdateGlobeNewswiresunRIZE enrollment on track including U.S. sites and expected to be completed in May 2025; topline data anticipated in December 2025 U.S. Food and Drug Administration (FDA) grants Breakthrough Therapy Designation to
- 1y agoRZLTRezolute Receives Breakthrough Therapy Designation from FDA for Ersodetug in the Treatment of Hypoglycemia Due to Tumor HyperinsulinismGlobeNewswireRegistrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year Designation underscores need for therapies to treat severe hypoglycemia in the oncology setting REDWOOD CITY, Calif., May